Viatris Gross Margin 2010-2024 | VTRS
Current and historical gross margin for Viatris (VTRS) over the last 10 years. The current gross profit margin for Viatris as of December 31, 2024 is %.
| Viatris Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-12-31 |
$14.74B |
$5.62B |
38.15% |
| 2024-09-30 |
$15.05B |
$6.01B |
39.91% |
| 2024-06-30 |
$15.24B |
$6.24B |
40.93% |
| 2024-03-31 |
$15.36B |
$6.40B |
41.67% |
| 2023-12-31 |
$15.43B |
$6.44B |
41.74% |
| 2023-09-30 |
$15.47B |
$6.12B |
39.54% |
| 2023-06-30 |
$15.60B |
$6.17B |
39.57% |
| 2023-03-31 |
$15.80B |
$6.27B |
39.66% |
| 2022-12-31 |
$16.26B |
$6.50B |
39.94% |
| 2022-09-30 |
$16.73B |
$6.77B |
40.46% |
| 2022-06-30 |
$17.19B |
$6.59B |
38.36% |
| 2022-03-31 |
$17.65B |
$6.22B |
35.24% |
| 2021-12-31 |
$17.89B |
$5.58B |
31.17% |
| 2021-09-30 |
$17.17B |
$4.74B |
27.58% |
| 2021-06-30 |
$15.60B |
$4.32B |
27.69% |
| 2021-03-31 |
$13.76B |
$4.02B |
29.21% |
| 2020-12-31 |
$11.95B |
$3.80B |
31.78% |
| 2020-09-30 |
$11.51B |
$4.18B |
36.29% |
| 2020-06-30 |
$11.50B |
$4.09B |
35.56% |
| 2020-03-31 |
$11.63B |
$4.00B |
34.39% |
| 2019-12-31 |
$11.50B |
$3.90B |
33.88% |
| 2019-09-30 |
$11.39B |
$3.83B |
33.59% |
| 2019-06-30 |
$11.29B |
$3.79B |
33.60% |
| 2019-03-31 |
$11.25B |
$3.82B |
34.00% |
| 2018-12-31 |
$11.43B |
$4.00B |
35.00% |
| 2018-09-30 |
$11.59B |
$4.28B |
36.92% |
| 2018-06-30 |
$11.72B |
$4.42B |
37.72% |
| 2018-03-31 |
$11.87B |
$4.68B |
39.43% |
| 2017-12-31 |
$11.91B |
$4.78B |
40.17% |
| 2017-09-30 |
$11.94B |
$4.82B |
40.40% |
| 2017-06-30 |
$12.01B |
$4.93B |
41.04% |
| 2017-03-31 |
$11.61B |
$4.88B |
42.00% |
| 2016-12-31 |
$11.08B |
$4.70B |
42.40% |
| 2016-09-30 |
$10.30B |
$4.43B |
42.96% |
| 2016-06-30 |
$9.94B |
$4.46B |
44.85% |
| 2016-03-31 |
$9.75B |
$4.29B |
44.04% |
| 2015-12-31 |
$9.43B |
$4.22B |
44.71% |
| 2015-09-30 |
$9.02B |
$4.12B |
45.69% |
| 2015-06-30 |
$8.41B |
$3.82B |
45.40% |
| 2015-03-31 |
$7.88B |
$3.62B |
45.96% |
| 2014-12-31 |
$7.72B |
$3.53B |
45.70% |
| 2014-09-30 |
$7.45B |
$3.36B |
45.06% |
| 2014-06-30 |
$7.13B |
$3.15B |
44.21% |
| 2014-03-31 |
$6.99B |
$3.09B |
44.11% |
| 2013-12-31 |
$6.91B |
$3.04B |
44.01% |
| 2013-09-30 |
$6.82B |
$2.99B |
43.77% |
| 2013-06-30 |
$6.86B |
$2.97B |
43.32% |
| 2013-03-31 |
$6.85B |
$2.93B |
42.83% |
| 2012-12-31 |
$6.80B |
$2.91B |
42.78% |
| 2012-09-30 |
$6.61B |
$2.81B |
42.56% |
| 2012-06-30 |
$6.38B |
$2.68B |
41.95% |
| 2012-03-31 |
$6.27B |
$2.64B |
42.17% |
| 2011-12-31 |
$6.13B |
$2.56B |
41.81% |
| 2011-09-30 |
$6.03B |
$2.50B |
41.39% |
| 2011-06-30 |
$5.81B |
$2.42B |
41.62% |
| 2011-03-31 |
$5.61B |
$2.29B |
40.88% |
| 2010-12-31 |
$5.45B |
$2.22B |
40.68% |
| 2010-09-30 |
$5.37B |
$2.15B |
40.13% |
| 2010-06-30 |
$5.28B |
$2.08B |
39.40% |
| 2010-03-31 |
$5.18B |
$2.07B |
39.90% |
| 2009-12-31 |
$5.09B |
$2.08B |
40.74% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$10.258B |
$14.739B |
|
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
|
